Consistent data from high-quality clinical studies will better inform clinical practices, guidelines and policy decisions, ...

Mayo Clinic researchers found that a gene variant, the TPMT∗8 allele, is associated with reduced metabolism of the thiopurine ...

Pharmacogenomic (PGx) testing is a growing area of personalized medicine with demonstrated clinical utility in improving patient outcomes in oncology. PGx testing of pharmacogenes affecting drug ...

If a pharmacogenomic test result can significantly impact on a treatment decision, either to contraindicate usage of a drug or biologic agent or adjust dosing, product labeling should be modified ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today provided an update on its engagement with UnitedHealthcare (UNH) following the Nov 1, 2024 publication ...

Mayo Clinic researchers found that a gene variant, the TPMT ∗ 8 allele, is associated with reduced metabolism of the ...

They also suggest that a pharmacogenomic test may one day be available that can give physicians the opportunity to not only be aware of a particular patient's risk, but be able to weigh the ...

Mayo Clinic researchers found that a gene variant, the TPMT∗8 allele, is associated with reduced metabolism of the thiopurine class of drugs. TPMT∗8 is relatively common in individuals of African or ...

In addition, they emphasized that the CPIC (Clinical Pharmacogenetics Implementation Consortium) and FDA (Food and Drug Administration) advocate for the use of PGx testing, specifically testing CYP2D6 ...

The genetic testing market accounted for $ 12,682 million in 2019, and is expected to reach $ 21,260 million by 2027, registering a CAGR of 10.1% from 2020 to 2027. The global genetic testing market ...

Pharmacogenomic testing, which identifies how genetic differences affect drug responses, is also gaining traction in personalized medicine. Genetic testing is increasingly used to assess the risk ...